LianBio, a biopharmaceutical company located in Princeton, NJ, is committed to developing and releasing drugs for a variety of illnesses, including cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian markets. The company is creating a range of new therapies, including Mavacamten for non-obstructive hypertrophic cardiomyopathy and heart failure, TP-03 for Demodex blepharitis, and NBTXR3 for the treatment of head and neck squamous cell carcinoma and solid tumors, among others. It is collaborating with Tarsus Pharmaceuticals, Inc. for TP-03 and Nanobiotix S.A. for NBTXR3 to provide access to these positive new medicines.